Introduction
Activin A is highly homologous with transforming growth factor (TGF)-b and consists of two bA subunits (Vale et al., 1986; Ling et al., 1986) . It was initially recognized as a gonadal protein that stimulates the release of follicular-stimulating hormone (FSH) from the pituitary gland (Vale et al., 1986; Ling et al., 1986) . Several studies have shown that activin A carries out a variety of functions including regulation of hematopoiesis (Eto et al., 1987; Yu et al., 1989; Yamashita et al., 1991) . Activin A induces dierentiation of murine Friend leukemia cell line and human leukemia cell line K562 cells into hemoglobin (Hb)-containing cells (Murata et al., 1988; Miyamoto et al., 1990) ; it also modulates dierentiation and proliferation of immature erythroid progenitor cells (Broxmeyer et al., 1988; Shao et al., 1992; Mizuguchi et al., 1993) . We have recently isolated an inhibitory factor for mouse B cell hybridoma cells from the culture media of activated mouse macrophages and identi®ed this molecule as being identical to activin A (Nishihara et al., 1993) . In addition, we have found that activin A induces cell cycle arrest during the G1 phase. Moreover, it induces apoptosis in mouse plasmacytic cells and human myeloma cells (Koseki et al., 1995; Yamato et al., 1996 Yamato et al., , 1997 . It has been shown that activin A might act as a commitment factor for inducing cellular apoptosis and dierentiation as a manner of induction or suppression of gene expression (Shiozaki et al., 1998) . However, the mechanism of growth inhibitory eects of activin A in hematopoietic cells has not been elucidated.
The Bcl-2 family of proteins are key regulators of apoptosis in many cell types. This family of proteins consists of pro-apoptotic (Bax, Bad, and Bak) and anti-apoptotic (Bcl-2, Bcl-X L , and Mcl-1) subfamilies (Yang and Korsmeyer, 1996; Kroemer, 1997; Gross et al., 1999) . Pro-and anti-apoptotic family members can heterodimerize with each other and the balance of these members may act as a rheostar for the suicide program that determines the activities of cell fate (Peters et al., 1998; Moulding et al., 1998; Shimizu et al., 2000; Kroemer and Reed, 2000) . Mcl-1, one of the anti-apoptotic Bcl-2 family members, heterodimerizes with Bax, and neutralizes the cytotoxicity induced by Bax (Sato et al., 1994; Zhou et al., 1997) . Mcl-1 is also able to protect CHO cells from apoptosis induced by c-myc overexpression (Reynolds et al., 1994) . This protein was originally identi®ed as a novel gene induced early in the induction of dierentiation of the human myeloid leukemia cell line ML-1. Expression of Mcl-1 mRNA is rapidly up-regulated with the treatment of 12-O-tetradecanoylphorbol-13-acetate (TPA) during the dierentiation process in ML-1 cells; this process is followed by rapid degradation of Mcl-1 (Kozopas et al., 1993) . Mcl-1 contains two PEST motifs which probably leads itself to a labile protein with a short half-life (Kozopas et al., 1993; Yang et al., 1995) . Mcl-1 is thus thought to be a rapidly inducible, short-term eector of cell viability Moulding et al., 1998; Chao et al., 1998) . However, the physiological function of Mcl-1 in leukemic cells is still unclear.
In the present study, we examined the role of Mcl-1 during the induction of apoptosis and dierentiation of CML cells in the treatment of activin A. In both activin A-induced apoptosis and dierentiation pathways of CML, Mcl-1 is rapidly induced, and subsequent molecular events may aect the cell fate.
Results

Effects of activin A on cellular proliferation of KU812 and K562 cells
The eects of activin A on the proliferation of human CML cells were examined using KU812 and K562 cells. The cells were cultured with activin A (50 ng/ml) for the indicated durations or treated with various concentrations of activin A (0 ± 100 ng/ml) for 96 h (Figure 1a ± d) . Activin A decreased the number of viable cells in both cell lines in a time-and dose- Figure 1 Time-and dose-dependent eects of activin A on the cellular proliferation of CML cells. KU812 cells (a,c) and K562 cells (b,d) were cultured with 50 ng/ml of activin A for various durations (0 ± 120 h) (a,b) or in various concentrations of activin A (0 ± 100 ng/ml) for 96 h (c,d). Cell viability was estimated by Trypan blue dye exclusion test. These experiments were performed 3 ± 5 times. Results were expressed as the mean+s.d. dependent manner (Figure 1a ± d) . Both cell lines were sensitive for activin A and the growth inhibition was observed at a low concentration or a short-term culture. However, activin A was not able to induce complete growth arrest of both cell lines.
Activin A-induced apoptosis and differentiation of CML cells
To elucidate the mechanism of activin A-induced growth suppression of KU812 and K562 cells, we next examined the biological events of these cells. Exposure of KU812 cell to activin A (50 ng/ml) for 96 h resulted in an increase of annexin V-positive and PI-negative cells (Figure 2a ) and exhibited a striking DNA ladder formation ( Figure 2b ). Moreover, treatment of KU812 cells with activin A did not induce the dianisidinepositive and hemoglobin (Hb) containing cells (Figure 2c, d) . These results indicate that activin A inhibits the cellular growth of KU812 cells via the induction of apoptosis, but not dierentiation. In contrast, treatment with activin A (50 ng/ml) for 96 h did not increase a number of annexin V-positive cells ( Figure  2a) , and increased the ratio of dianisidine-positive cells from 17 ± 19% to 57 ± 68% of K562 cells (Figure 2c ). In addition, expression of Hb in K562 cells was increased by activin A in a time-dependent manner (Figure 2d ), suggesting that activin A induced dierentiation of K562 cells as previously reported (Yu et al., 1987; Frigon et al., 1992) . 
Expression of apoptosis-associated proteins in activin A-treated cells
To address the mechanisms of activin A-induced apoptosis in KU812 cells, the expression of apoptosis-associated proteins was examined by Western blot analysis. The level of Mcl-1 protein rapidly increased by 30 min and continued to increase at 12 h of culture with activin A (50 ng/ml) in both KU812 and K562 cells (Figure 3a) . Interestingly, Bax protein was also induced in KU812 cells after 30 min, and activation of caspase-9 and -3 was observed after 24 ± 48 h of exposure to activin A, resulting in the cleavage of DFF45/ICAD, an inhibitor of DFF40/CAD (Figure 3a ± c). In marked contrast to KU812 cells, the levels of Bax protein were not modulated by treatment with activin A in K562 cells (Figure 3a ). The levels of caspase-9 and -3, and DFF45 proteins were not changed in K562 cells (Figure 3b, c) . Activin A did not aect the expression of the anti-apoptotic protein, Bcl-2, but caused continuous up-regulation of another anti-apoptotic protein, Bcl-X L , in both KU812 and K562 cells (Figure 3a) . Furthermore, the activated form of caspase-8 was not detected in KU812 cells (data not shown).
Inhibition of activin A-induced apoptosis in KU812 cells by caspase inhibitors
Caspase is known to play a pivotal role in apoptosis (Los et al., 1999) . In order to elucidate the functional role of caspase-9 and -3 in the activin A-induced Figure 3 Expression of apoptosis-associated proteins in both activin A-treated CML cells. Cell lysate were prepared for various incubation time (0 ± 96 h) with activin A (50 ng/ml). Total cellular proteins (20 mg/lane) were separated on 12.5% SDSpolyacrylamide gels and analysed by Western blot analysis. Expression of the Bcl-2 family proteins (a), caspase family proteins (b), and DFF45 (c) in KU812 and K562 cells apoptosis of KU812 cells, a series of speci®c caspase inhibitors were evaluated for their ability to inhibit activin A-induced apoptosis. Boc-D-FMK (a general caspase inhibitor), Ac-LEHD-CHO (caspase-9 inhibitor), and Ac-DEVD-CHO (caspase-3 inhibitor) were considered. These inhibitors (1 mM and 50 mM) were added to KU812 cells and incubated with activin A (50 ng/ml) for 72 h. As shown in Figure 4 , all of these caspase inhibitors inhibited activin A-induced apoptosis in a dose-dependent manner.
Effect of EPO on activin A-induced apoptosis and differentiation in CML cells
EPO is a survival factor for erythroid cells; it protects them from apoptosis and supports lineage-speci®c dierentiation (Shiozaki et al., 1998) . To clarify the eects of EPO on activin A-induced growth suppression, KU812 and K562 cells were cultured for 96 h with activin A (50 ng/ml), EPO (2 IU/ml) and with both agents. In KU812 cells, EPO alone increased the number of viable cells by 1.5-fold, as compared to the increase in the control cells (Figure 5a ). In addition, EPO also blocked activin A-induced apoptosis ( Figure  5b 
Effects of Mcl-1 overexpression on activin A-induced apoptosis in KU812
Transient up-regulation of Mcl-1 is important for cell fate decision of dierentiation or apoptosis Zhou et al., 1997; Moulding et al., 1998) . As regards our results, they suggest that treatment with activin A and EPO resulted in prolonged expression of Mcl-1 in KU812 cells, which in turn induced dierentiation to Hb synthesizing cells. Therefore, KU812 and K562 cells that expressed high levels of exogeneous Mcl-1 in a stable manner were established by introduction of Mcl-1 plasmid, driven by the SRa promoter, these cells were designated as KU812/mcl and K562/mcl. We have established 13 clones of KU812/mcl cells and individual levels of Mcl-1 are shown in Figure 6a . KU812/mcl clone 7 and clone 9 were highly expressed Mcl-1 protein, therefore, we used these clones for the following experiments. KU812 and K562 cells transfected with control plasmid (SRa-neo) were used as control cells (KU812/neo and K562/neo, respectively). Activin A did not modulate the expression of Bax protein at 72 h of treatment and maintained the expression of the DFF40/DFF45 complex for 72 h in KU812/mcl cells (clone 7 and clone 9), whereas prolonged expression of Bax and low DFF complex levels were observed in activin A-treated parental and control KU812/neo cells (Figure 6b ). In addition, activin A induced the accumulation of Hb in both clones of KU812/mcl cells at 72 h (Figure 6c) , suggesting that activin A induced dierentiation into erythroid cells, but not apoptosis, of KU812 cells that expressed high levels of Mcl-1. These ®ndings are similar to the results of the study of EPO combined activin A-treated KU812 cells (Figure 5a ± d) . The expression pattern of these proteins, as well as the biological eects of activin A in KU812/neo cells, was similar to that of the parental KU812 cells (Figure 6b ,c and data not shown). K562/mcl cells showed similar sensitivity to activin A-induced growth suppression, as compared to that of the control K562/neo cells. Moreover, both control and Mcl-1-expressing K562 cells were induced to dierentiate by treatment with activin A (50 ng/ml) for 72 h (data not shown).
Discussion
Activin A is a member of the TGF-b superfamily that may exert a broad range of eects on growth, dierentiation, and maturation in various cell types, including hematopoietic cells (DePaolo et al., 1991; Nishimura et al., 1991; Bilezikjian and Vale, 1992; Mather et al., 1992) . Activin A was identi®ed as being identical to erythroid dierentiation factor (EDF), which is known to inhibit proliferation of murine Friend erythroleukemia cells and human CML cell line Figure 4 Eect of caspase inhibitors on activin A-treated KU812 cells. Inhibition of activin A-induced (50 ng/ml, 72 h) apoptosis of KU812 cells was estimated in a co-culture with a series of speci®c caspase inhibitors (1 mM and 50 mM). These experiments were repeated 3 ± 5 times. Results were expressed as the mean+s.d. Left: a general caspase inhibitor, Boc-D-FMK. Center: caspase-9 inhibitor, Ac-LEHD-CHO. Right: caspase-3 inhibitor, Ac-DEVD-CHO Figure 5 Eect of EPO on activin A-induced apoptosis and erythroid dierentiation of CML cells. KU812 and K562 cells were cultured with 50 ng/ml of activin A (A), 2 IU/ml of EPO (E), or both agents (A+E) for 96 h. Cell growth and viability were examined with Trypan blue dye exclusion test (a), and apoptosis was con®rmed by DNA fragmentation analysis (b). Expression of Mcl-1, Bax, and Hb contents were analysed by Western blot analysis in the presence of activin A (50 ng/ml)-, EPO (2 IU/ml)-, or both (A+E)-treated KU812 and K562 cells for 6 or 72 h (c). In addition, levels of DFF45 and Hb contents were examined in KU812 cells for 72 h with treatment of activin A (50 ng/ml) and the combination of activin A and EPO (2 IU/ml) (d). M, marker; C, control; A, activin A; E, EPO K562 (Eto et al., 1987; Murata et al., 1988) and induce dierentiation into Hb synthesizing erythroblasts (Yu et al., 1987; Frigon et al., 1992; Lebrun and Vale, 1997) . In addition, activin A was able to directly or indirectly modulate the proliferation of human erythroid progenitor cells Mizuguchi et al., 1993) . In the present study, we demonstrate that activin A can inhibit the proliferation of CML cell lines by both inducing apoptosis in KU812 cells and dierentiation of K562 cells. We found for the ®rst time that rapid and transient up-regulation of Mcl-1 by the treatment of activin A was observed in both cases, and a subsequent increase of Bax protein resulted in inducing apoptosis in KU812 cells. Therefore, Mcl-1 seems to be an early-inducible molecule in the signaling pathway of activin A-induced growth suppression of CML cells.
Mcl-1 has sequence similarity to Bcl-2 family members, and originally was identi®ed as a gene induced early in the process of dierentiation of ML-1 myeloid leukemia cells in the treatment with TPA (Kozopas et al., 1993) , and prevent apoptosis in c-mycoverexpressing CHO cells (Reynolds et al., 1994) . Mcl-1 has two PEST motifs that can be degraded rapidly (Kozopas et al., 1993; Yang et al., 1995) . Thus, one possible role of this protein could be to function as a rapid turnover eector that controls the rate of apoptosis and the fate of certain cells. The dierence between activin A-induced apoptosis and dierentiation may depend on the continuous induction of Bax protein followed by transient upregulation of Mcl-1 protein. In KU812 cells, activated caspase-9 and caspase-3, induced by treatment with activin A, were expressed from 24 h after the downregulation of Mcl-1 protein had occurred. In contrast, Hb was induced to accumulate in KU812 cells after 72 h exposure to activin A and EPO, a survival factor for erythroid cells. Therefore, apoptotic signals induced by activin A via the induction of Mcl-1, is faster and probably stronger than the corresponding dierentiation signals; the continuous expression of Bax protein may be important for the course that leads to apoptosis of the cells. Moreover, direct interaction between continuous up-regulated Mcl-1 and Bax protein, or indirected association of both proteins through the regulation of the mitochondrial apoptotic change, may defeat the subsequent apoptotic signals (Zhou et al., 1997; Vander Heiden and Thompson, 1999; Kroemer and Reed, 2000) . In contrast the Figure 6 Eect of Mcl-1 overexpression on activin A-induced apoptosis in KU812 cells. pSRa-neo-EAT/mcl-1 and pSRa-neo were transfected in KU812 cells by the Eectine transfection method. Thirteen clones of mcl-1 transfected KU812 cells were established (a). After mcl-1-overexpressed KU812 cells (KU812/ mcl) were selected (clone 7 and clone 9), they were stimulated with activin A (50 ng/ml, 6 and 72 h). The cell lysate was analysed by Western blot analysis for apoptosis-associated proteins (b) and Hb expression (c) mechanism of KU812 cells, activin A induced dierentiation of K562 cells into erythroid cells without modulating the Bax protein. A recent investigation showed that one murine cell line, ELM-I-1, required both activin A and EPO to achieve erythroid dierentiation, however, in that study, apoptosis was induced by treatment with activin A alone. On the contrary, in another murine cell line, F5-5, dierentiation was suciently induced by activin A alone to achieve an erythroid lineage (Shiozaki et al., 1998) . One possible explanation for these dierences in activin A reactivity in these two cell lines was the state of the EPO receptor. Namely, it has been reported that the EPO receptor is constitutively activated in F5-5 cells, whereas it is not activated in ELM-I-1 cells (Li et al., 1990; Shiozaki et al., 1998) . These results suggest that the survival signaling molecules and pathways, including the STAT5 or PI3K/Akt pathway (Smithgall et al., 2000; Haseyama et al., 1999; Wang et al., 1999) , may dierentiate among cell lines. However, the present results indicate that overexpression of Mcl-1 may inhibit activin A-induced apoptosis, and subsequent inhibition of apoptosis may support cellular dierentiation of CML cells. Therefore, overexpression of Mcl-1 can protect against apoptosis. Moreover, Mcl-1 plays a role in the survival function of the activin A signaling pathway.
CML is a clonal stem cell disorder characterized by increased proliferation of myeloid cells at all stages of dierentiation (Champlin and Golde, 1985) . Interferona and hematopoietic stem cell transplantation have been clinically introduced and established as a standard therapy for patients with CML. However, higher dosages of interferon-a often are accompanied by troubling side eects; in addition, patients in the blastic phase of the disease do not respond to this treatment (Talpaz and Kantarjian, 1995) . Stem cell transplantation often causes serious clinical side eects and elderly patients undergo the risk of early mortality. Therefore, a novel therapeutic approach is strongly desired. Further studies using clinical materials and in vivo studies will be necessary for establishing the appropriate clinical application of activin A for patients with CML. Nonetheless, activin A remains a possible candidate for a novel therapeutic agent that mediates apoptosis and the dierentiation of leukemic cells.
In summary, we report here for the ®rst time that activin A can induce both apoptosis and the dierentiation of CML cells with transient up-regulation of Mcl-1. Mcl-1 is an early-inducible molecule in the signaling pathway of activin A, and contributes to the cell fate decision.
Materials and methods
Cells and cytokine
Human CML cell lines (KU812 and K562 cells) were obtained from the Japanese Cancer Research Resources Bank (JCRB; Tokyo, Japan) and were maintained in RPMI 1640 medium (GIBCO-BRL, Gaitherburg, MD, USA) with 10% fetal bovine serum (FBS, GIBCO-BRL), 100 U ml 71 penicillin, and 100 mg/ml streptomycin (Sigma Chemical Co., St. Louis, MO, USA) in a humidi®ed atmosphere with 5% CO 2 . Recombinant human activin A was kindly provided by Dr Y Eto (Ajinomoto Co., Inc., Tokyo, Japan) and recombinant human erythropoietin (EPO) was a gift from Kirin Brewery Co., Ltd. (Tokyo, Japan). Both agents dissolved in RPMI 1640 medium at a stock concentration of 250 mg/ml and 1000 IU/ml, respectively.
Assays for cellular proliferation
Cellular proliferation was evaluated by Trypan blue dye exclusion test. Cells (1610 6 ) were cultured with various concentrations of activin A (0 ± 100 ng/ml) for 96 h or with 50 ng/ml of activin A for various amounts of time (0 ± 120 h). Moreover, cells (1610 6 ) were cultured with 50 ng/ml of activin A with or without EPO (2 IU/ml) for 96 h. These experiments were performed 3 ± 5 times.
Analysis of apoptotic cells
The number of apoptotis cells was estimated with annexin V-FITC and Propidium Iodide (PI) staining and DNA fragmentation analysis. Activin A-stimulated (50 ng/ml, 0 ± 96 h) KU812 and K562 cells were stained with annexin V-FITC and PI double staining by using a staining kit purchased from PharMingen (San Diego, CA, USA) and the stained cells were analysed by a FACSCalibur (Becton Dickinson, Mountain View, CA, USA). In the DNA fragmentation analysis, cells (1610 6 ) were washed twice with ice-cold PBS and incubated in a lysis buer [10 mM Tris-HCl (pH 7.4), 10 mM EDTA (pH 8.0), 0.5% Triton X-100] at 48C for 10 min. After centrifugation, supernatants were incubated with RNase A (50 mg/ml, Sigma) for 1 h and with proteinase K (100 mg/ml, Sigma) for an additional hour at 378C. After isopropanol-precipitation, DNA was subjected to electrophoresis on 2% agarose gel and then it was stained with ethidium bromide.
Dianisidine staining
Hemoglobin concentrations were estimated with dianisidin staining. Activin A (50 ng/ml, 96 h)-stimulated KU812 and K562 cells (1610 6 ) were incubated in PBS containing 0.2% 3,3'-dimethoxybenzidine, fast blue B (dianisidine, Sigma), 0.3% H 2 O 2 for 30 min at room temperature without light. After incubation, cells were washed and resuspended (1610 6 / ml) with PBS.
Cell lysate preparation and Western blotting
After stimulation with activin A (50 ng/ml), EPO (2 IU/ml), or with both agents for various incubation times, cells were washed and suspended in lysis buer [1% NP-40, 1 mM PMSF, 40 mM Tris-HCl (pH 8.0), 150 mM NaCl] at 48C for 15 min. After centrifugation, supernatants were collected and protein concentrations were determined using a Bio-Rad protein assay system (Bio-Rad, Richmond, CA, USA). Cell lysates (20 mg of protein per lane) were fractionated in 12.5% SDS-polyacrylamide gel prior to transfer to the membrane (Immobilon-P membranes, Millipore, Bedford, MA, USA) using the standard protocol. Membranes were blocked overnight with 10% defatted milk in PBS containing 0.1% Tween 20 (PBS-T) at 48C. Antibodies were used at 1 : 500 ± 2500 dilution in 5 ± 10% defatted milk in PBS-T for 1 h at 258C. Subsequently, membranes were incubated with anti-rabbit Ig conjugated with horseradish peroxidase (-HRP) (1 : 1000, Amersham, Buckinghamshire, UK), antimouse 1g-HRP (1 : 1000, Amersham) or anti-goat IgG-HRP (1 : 2500, Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at 258C. Antibody binding was detected by using an enhanced chemiluminescence kit for Western blotting detection with Hyper®lm ECL (Amersham). Blots were stained with Coomassie brilliant blue and con®rmed to contain a similar amount of protein extract on each lane. Antibodies used in this study were as follows: anti-Mcl-1 (S-19), -Bax (H-20), -Bcl-XL (S-18), -caspase-8 [Mch5 p20 (c-20)] (Santa Cruz), anti-Bcl-2 (clone 124) (BoehringerMannheim, Indianapolis, IN, USA), anti-caspase-9, -caspase-3 (PharMingen), anti-DFF (CT) (Millennium Biotechnology, Ramona, CA, USA), and anti-Hemoglobin (DAKO A/S, Glostrup, Denmark).
Caspase inhibitory assay
KU812 cells (1610 6 ) were cultured with 50 ng/ml of activin A containing 1 or 50 mM of caspase inhibitors [caspase Inhibitor III (Boc-D-FMK), caspase-9 Inhibitor II (Ac-LEHD-CHO), caspase-3 Inhibitor I (Ac-DEVD-CHO); CALBIOCHEM, La Jolla, CA, USA] for 72 h. Cellular proliferation of activin A plus each inhibitor was evaluated by Trypan blue dye exclusion test. These experiments were performed 3 ± 5 times.
Plasmid and transfection
pSRa-neo-EAT/mcl-1 containing the full-length coding region of the human Mcl-1 cDNA was originally constructed in our laboratory (Ando et al., 1998) . The control plasmid pSRa-neo was constructed by cloning the neomycin resistant gene-containing fragment into EcoRI/HindIII-digested pBR322-SRa. Exponentially growing KU812 and K562 cells (1610 6 cells/60 mm dish) were transfected with either 0.4 mg of pSRa-neo-EAT/mcl-1 or pSRa-neo by the Eectine transfection method (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Forty-eight hours after transfection, cells were suspended in RPMI 1640 medium containing 600 mg/ml of G418 (GIBCO-BRL) for approximately 4 ± 6 weeks. Stable transfectants were screened for Mcl-1 expression by Western blot analysis, and single-cell clones expressing high levels of Mcl-1 were obtained by limiting dilution.
